Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ascendis Pharma A/S (ASND) vs Solaredge Technologies Inc (SEDG) Price & Performance

Ascendis Pharma A/STrade
Solaredge Technologies IncTrade

Price performance (Past 24H)

Key statistics

Ascendis Pharma A/S vs Solaredge Technologies Inc — how do they compare? Ascendis Pharma A/S trades at $254.87 (market cap $16.67B), while Solaredge Technologies Inc trades at $32.2 (market cap $2.05B). The key difference: Ascendis Pharma A/S is far larger — about 8.1× Solaredge Technologies Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Solaredge Technologies Inc nearer its low. Which is the better fit depends on your goals.

ASNDSEDG
Market Cap
$16.67B$2.05B
Sector
HealthTechnology
52-Week High
$277.18$78.51
52-Week Low
$189.74$25.10
Enterprise Value
$17.04B$1.91B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ascendis Pharma A/S

Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.

ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.

Solaredge Technologies Inc

SolarEdge Technologies (SEDG) trades at $32.34, up 0.4% on the day, amid a challenging period marked by negative profitability and a bearish technical signal. Recent Q2 2026 earnings beat expectations with a surprise profit, but weak Q3 guidance and a net loss under GAAP accounting highlight ongoing struggles. The stock faces headwinds from soft U.S. residential demand and policy dependency, while European growth offers some offset. Analyst sentiment is mixed, with a consensus price target of $35.15 but a majority hold rating reflecting execution risks.

The outlook remains cautious due to persistent losses, high debt, and volatile cash flows. Investment opportunity hinges on margin recovery and policy support, but risks include competitive pressures, liquidity concerns, and macroeconomic sensitivity. Near-term performance will depend on Q3 results and U.S. market trends.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.

Read more on ASND

About Solaredge Technologies Inc

SolarEdge Technologies designs, develops, and sells direct current optimized inverter systems for solar photovoltaic installations. The company system consists of power optimizers, inverters, and cloud-based monitoring platform and addresses a broad range of solar market segments, from residential solar installations to commercial and small utility-scale solar installations. The company sells its products directly to solar installers, engineering, procurement, and construction firms and indirectly to solar installers through distributors and electrical equipment wholesalers. Additionally, the company has nonsolar products targeting energy storage and e-mobility.

Read more on SEDG